10x Genomics (TXG) Net Cash Flow (2018 - 2026)

10x Genomics has disclosed Net Cash Flow across 9 years of filings, most recently posting $12.3 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 39.6% year-over-year to $12.3 million; the TTM figure through Jun 2026 stood at $104.9 million (up 498.45% YoY), while the FY2025 annual figure was $129.4 million, up 959.73% from the prior year.
• Net Cash Flow came in at $12.3 million for Q2 2026 at 10x Genomics, down from $16.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $112.4 million in Q1 2023 to a low of -$275.9 million in Q1 2022.
• Average Net Cash Flow over 5 years is -$5.2 million, with a median of $14.3 million recorded in 2026.
• Year-over-year, Net Cash Flow tumbled 903.58% in 2022 and surged 1051.66% in 2025.
• Over 5 years, Net Cash Flow stood at -$14.4 million in 2022, then jumped by 407.79% to $44.5 million in 2023, then sank by 221.03% to -$53.8 million in 2024, then surged by 176.57% to $41.2 million in 2025, then sank by 70.26% to $12.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $12.3 million in Q2 2026, $16.4 million in Q1 2026, and $41.2 million in Q4 2025.